安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- label - accessdata. fda. gov
These highlights do not include all the information needed to use REDEMPLO® safely and effectively See full prescribing information for REDEMPLO
- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include . . .
HIGHLIGHTS OF PRESCRIBING INFORMATION nfo REDEMPLO (plozasiran) injection, for subcutaneous use Initial U S Approval: 2025
- Highlights of Prescribing Information - Just the Inserts
The Adverse Reactions section in the Highlights of Prescribing Information is only a summary and not exhaustive Later on, the manufacturer will provide more information about two kinds of adverse reactions The first is Clinical Trials Experience where reactions from the product’s clinical trials are listed
- OPDIVO QVANTIG U. S. Prescribing Information
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO QVANTIG safely and effectively See full prescribing information for OPDIVO QVANTIG
- POHERDY - organon. com
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use POHERDY safely and effectively See full prescribing information for POHERDY POHERDY® (pertuzumab-dpzb) injection, for intravenous use Initial U S Approval: 2025
- What are the highlights for a clinical trial with Sotatercept (ACE-011)?
From the FDA Drug Label HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WINREVAIR safely and effectively See full prescribing information for WINREVAIR WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use Initial U S Approval: 2024 INDICATIONS AND USAGE WINREVAIR is an activin signaling inhibitor indicated for the
- Labeling for Human Prescription Drug and Biological Products . . .
Labeling includes three sections: Highlights of Prescribing Information (Highlights), a Table of Contents (Contents), and the Full Prescribing Information (FPI)
- KOMZIFTITM - kuraoncology. com
FULL PRESCRIBING INFORMATION WARNING: DIFFERENTIATION SYNDROME KOMZIFTI Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury,
|
|
|